Health Condition 1: F200- Paranoid schizophrenia
Conditions
Interventions
Intervention1: To assess the effect of Lumateperone as an adjunctive treatment for 6 weeks for negative symptoms and
cognitive deficit in schizophrenia.: 30 patients receiving Cap. Lumateperone (42mg
Sponsors
Central Institute Of Psychiatry, Ranchi
Eligibility
Inclusion criteria
Inclusion criteria: 1. participants satisfying the ICD-11 criteria for schizophrenia 2.illness duration of equal to or more than 2 years 3. patient giving written informed consent 4. score less than or equal to 25 in Hindi Montreal cognitive assessment test 5. PANSS negative symptoms score of equal to or more than 4 or more than 15 combined. 6. SANS score more than 20
Exclusion criteria
Exclusion criteria: 1. Any other major comorbid psychiatric diagnosis or significant concurrent medical illness. 2. Patients with organic brain disorder and/or mental retardation. 3. Patients on treatment with medications that can influence cognitive functioning: Anticholinergics (except trihexyphenidyl). 4. Patients who have received ECT in the past 6 months. 5. Contraindications to use of Lumateperone.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in the severity of negative symptoms from baseline to 4 week SANS (Scale for Assessment of Negative Symptoms) total score and PANSS (Positive and Negative Syndrome Scale) negative subscale score. Timepoint: Baseline and 4 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in cognitive performance scores from baseline to 4 weeks. BACS (Brief Assessment of Cognition in Schizophrenia) composite score and MoCA (Montreal Cognitive Assessment) total score. Timepoint: Baseline and 4 weeks. | — |
Countries
India
Contacts
Public ContactDr Anjanik K Rajan
Central Institute of Psychiatry
Outcome results
None listed